medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2021, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2021; 66 (4)

The expression of hormone receptors as a predictive factor of response to treatment in patients with early and locally advanced breast cancer with HER2 overexpression in a private hospital

Andrade-Moreno RA, Amador-García G, Martínez-Herrera JF, Olivares-Beltrán GM

Language: Spanish
References: 16
Page: 258-262
PDF size: 269.48 Kb.


ABSTRACT

Introduction: Breast cancer is the leading cause of cancer-associated death in women. One of the multiple subtypes of this disease, known for the overexpression of the human epidermal growth factor receptor 2 (HER2) has a poor prognosis. The development of trastuzumab has significantly improved cancer outcomes in these patients, however, not all patients benefit from this therapy. Objective: To compare the rate of pathological complete response after neoadjuvant treatment in Mexican patients with early and locally advanced HER2+ breast cancer, and its relationship with the expression of hormone receptors. Material and methods: A descriptive study of a retrospective, single-center cohort of patients with early and locally advanced HER2+ breast cancer treated with chemotherapy and anti-HER2 therapy in the ABC Medical Center. Results: 35 patients were included in the study. The pathological complete response was achieved in 60% of the general population (21 patients). A higher percentage of patients achieving a complete pathological response was identified in the group of hormone receptor negative patients compared to hormone receptor positive patients. (83 versus 48%). Conclusion: In early and locally advanced stage HER2+ breast cancer, the lack of expression of hormone receptors is associated with a greater sensitivity to neoadjuvant treatment, determined by a greater percentage of patients who achieve a pathological complete response.


REFERENCES

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7-30.

  2. Henry NL et al. Cancer de mama. En: Niederhuber JE, Armitage JO, Doroshow JH, Kastan, Tepper, JE (Eds). Abeloff oncología clínica. 6th ed. Elsevier, Barcelona, España 2020, 1560-1603.

  3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2 (2): 127-137. doi: 10.1038/35052073.

  4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235 (4785): 177-182.

  5. Reynoso-Noverón N, Villareal-Garza C et al. Clinical and epidemiological profile of breast cancer in Mexico: results of the Seguro Popular. J Glob Oncol. 2017; 3(6): 757-764.

  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344 (11): 783-792.

  7. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001; 28 (5 Suppl 16): 4-11.

  8. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2- positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13 (1): 25-32.

  9. Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017; 377 (2): 122-131.

  10. Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30 (15): 1796-1804.

  11. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384 (9938): 164-172.

  12. I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020; 6 (9): 1355-1362.

  13. Gianni L, Pienkowski T, Im YH. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17 (6): 791-800.

  14. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24 (9): 2278-2284.

  15. Van Ramshorst MS, Van der Voort A, Van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19 (12): 1630-1640.

  16. Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol. 2018; 25 (7): 1783-1778.



EVIDENCE LEVEL

IV




2020     |     www.medigraphic.com